Is CJC-1295 DAC FDA approved?

CJC-1295 DAC is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

How is CJC-1295 DAC administered in research settings?

In research settings, CJC-1295 DAC is typically administered via the subcutaneous route. PeptideBase does not provide dosing or administration instructions.

How is Ipamorelin administered in research settings?

In research settings, Ipamorelin is typically administered via the subcutaneous route. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›CJC-1295 DAC vs Ipamorelin

Peptide Comparison

CJC-1295 DAC vs Ipamorelin

Name: CJC-1295 DAC vs Ipamorelin — Per-mg Price Comparison
Creator: PeptideBase
License: https://peptidebase.io/terms

Both are GH / IGF Axis peptides.

CJC-1295 DAC

CJC-1295 with DAC

Fat LossNot EvaluatedResearch Only

Half-life: 6–8 days

1 providers listed

Full CJC-1295 DAC profile →

Ipamorelin

NNC 26-0161

PerformanceUnder clinical reviewResearch Only

Half-life: 2 hours

463 providers listed

Full Ipamorelin profile →

Bottom line

CJC-1295 DAC has a longer half-life than Ipamorelin, so it generally needs less frequent dosing.

Quick Verdict

CJC-1295 DAC

Half-life

6–8 days

Ipamorelin

Half-life

2 hours

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	Ipamorelin
Less frequent dosing (longer half-life)	CJC-1295 DAC
Lower typical price per mg	Ipamorelin
More provider options (1 vs 463)	Ipamorelin

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

CJC-1295 DAC

Ipamorelin

Mechanism Family

GH / IGF Axis

Half-life

6–8 days

2 hours

FDA Status

not evaluated

Under clinical review

Admin Routes

subcutaneous

Availability

Research Only

Providers

1 listed

463 listed

FDA Update

—

Under clinical review

Avail. Notes

Long-acting GHRH analog with a Drug Affinity Complex (DAC) modification. No FDA approval. Not on the FDA 503A bulks list. WADA-prohibited as a growth hormone releasing factor. Sold as a research chemical only.

Selective GH secretagogue pentapeptide. Phase 2 by Helsinn (postoperative ileus) discontinued for lack of efficacy. No FDA approval. Not on FDA 503A bulks list. Research chemical.

Research Evidence

CJC-1295 DAC

RCT · 1 key study · dated evidence base — most recent 2006

Ipamorelin

RCT · 5 key studies · most recent 2026

Research Citations

CJC-1295 DAC

RCT2006 · Journal of Clinical Endocrinology and Metabolism

Effects of a single injection of CJC-1295, a long-acting growth hormone-releasing hormone analog, in healthy…

Ipamorelin

RCT2014 · International Journal of Colorectal Disease

Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the managem…

Animal2000 · J Endocrinol

GH secretagogues increase bone mineral content in adult female rats

Review2026 · Int J Mol Sci

Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications…

Review2026 · JBJS Rev

Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Imp…

+1 more

About CJC-1295 DAC

CJC-1295 DAC is a GHRH analog carrying a Drug Affinity Complex (DAC) modification that binds covalently to circulating albumin, greatly extending its plasma half-life relative to unmodified or short-acting GHRH analogs. Through this albumin binding it acts as a long-lasting agonist at pituitary GHRH receptors, associated in research with sustained growth hormone and downstream IGF-1 elevation. This contrasts with the non-DAC form (Mod GRF 1-29), whose action is measured in minutes rather than days.

Research Areas

GH and IGF-1 elevation studied in a single-dose human PK trialsustained GHRH-receptor agonism via albumin bindingextended plasma half-life relative to short-acting GHRH analogsbody-composition and GH-axis research contextssubcutaneous administration in published research

About Ipamorelin

Ipamorelin binds to the ghrelin receptor (GHSR-1a) and stimulates dose-dependent GH release with a clean hormonal profile. Unlike GHRP-6 or hexarelin, it does not significantly stimulate appetite-related pathways or cortisol secretion at standard research doses. This selectivity makes it a frequently studied peptide for protocols where hormonal side-effect profiles are a consideration.

Research Areas

selective GH release without cortisol or prolactin co-stimulationpulsatile GH secretion — synergistic with CJC-1295 in combination protocolslean mass support and fat metabolism via GH/IGF-1 axis modulationsubcutaneous injection 100–300 mcg; minimal receptor desensitization vs other GHRPs

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

CJC-1295 DAC

Warnings & Cautions

Active malignancy — caution (GH/IGF-1 is mitogenic)Pregnancy — cautionKnown hypersensitivityGlucose intolerance / insulin resistance

Class-based (investigational)

Suggested Monitoring

IGF-1Fasting glucoseHbA1cInsulin

Research protocols routinely measure IGF-1 to track GH axis activity before and during use. Fasting glucose and insulin are monitored because GH elevation can reduce insulin sensitivity over time.

Regulatory Notes

global — WADA

This compound falls under WADA Prohibited List category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), prohibited at all times for competing athletes.

source

Ipamorelin

Absolute Contraindications

Under clinical review

Being verified by our medical team before we display contraindications for this peptide.

Suggested Monitoring

IGF-1Fasting glucoseHbA1cInsulin

Research protocols routinely measure IGF-1 to track GH axis activity before and during use. Fasting glucose and insulin are monitored because GH elevation can reduce insulin sensitivity over time.

Regulatory Notes

global — WADA

This compound falls under WADA Prohibited List category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), prohibited at all times for competing athletes.

source

Used Together?

Ipamorelin

CJC-1295
Research suggests Ipamorelin and CJC-1295 may produce enhanced growth hormone release effects when combined. CJC-1295 provides sustained GHRH receptor stimulation while Ipamorelin provides pulsatile ghrelin receptor stimulation — complementary pathways studied in GH secretion research.
Sermorelin
Research suggests Sermorelin and Ipamorelin may produce complementary growth hormone release effects when combined. Sermorelin acts as a GHRH analogue via pituitary receptors, while Ipamorelin acts via ghrelin receptors — dual-pathway stimulation studied in GH optimization research.
GLP-1 agonists
Research notes metabolic pathway overlap between growth hormone-releasing peptides and GLP-1 agonists. Both compound classes influence metabolic signaling; limited research has studied their combined effects. Consult your prescriber before combining.

Price (per mg)

CJC-1295 DAC

$10.63/mg

$9.74 – $15.25 range

20 vendors

View price index →Find providers →

Ipamorelin

$6.48/mg

$4.88 – $8.05 range

51 vendors

View price index →Find providers →

Find Providers

Where to source these peptides

Providers offering

CJC-1295 DAC

1 listed

Browse directory →

Providers offering

Ipamorelin

463 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More GH / IGF Axis Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated August 26, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). CJC-1295 DAC vs Ipamorelin — Per-mg Price Comparison. Retrieved August 26, 2026, from https://peptidebase.io/peptides/compare/cjc-1295-dac/ipamorelin

https://peptidebase.io/peptides/compare/cjc-1295-dac/ipamorelin Methodology License Download JSON Download CSV